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Abstract 
Innovative and personalized therapeutic approaches result from the identification and control 
of individual aberrantly expressed genes at the transcriptional and post-transcriptional level. 
Therefore, it is of high interest to establish diagnostic, therapeutic and theranostic strategies 
at these levels. In the present study, we used the Diels-Alder Reaction with inverse electron 
demand (DARinv) click chemistry to prepare a series of cyclic RGD-BioShuttle constructs. 
These constructs carry the near-infrared (NIR) imaging agent Cy7 and the chemotherapeutic 
agent temozolomide (TMZ). We evaluated their uptake by and their efficacy against integrin 
αvβ3-expressing MCF7 human breast carcinoma cells. In addition, using a mouse phantom, we 
analyzed the suitability of this targeted theranostic agent for NIR optical imaging. We ob-
served that the cyclic RGD-based carriers containing TMZ and/or Cy7 were effectively taken 
up by αvβ3-expressing cells, that they were more effective than free TMZ in inducing cell 
death, and that they could be quantitatively visualized using NIR fluorescence imaging. 
Therefore, these targeted theranostic agents are considered to be highly suitable systems for 
improving disease diagnosis and therapy. 
Key words: BioShuttle, Click-Chemistry, inverse Diels Alder Reaction, Ligation chemistry, NIR 
Imaging, RGD, targeted Imaging, targeted Therapy, Temozolomide, Theranostics 
Introduction 
The rapid progress in genomic and proteomic 
research has contributed substantially to the devel-
opment of novel and more specific diagnostics and 
therapeutics. Such advanced interventions facilitate 
individualized and personalized treatment regimens, 
and increasingly involve diagnostics and therapeutics 
based on antibodies, peptides and nucleic acids. In the 
field of diagnostics, for instance, peptides and anti-
sense molecules coupled to contrast agents have been 
shown to be excellent tools for detecting aberrantly 
expressed receptors and mRNA in tumor cells using 
positron emission tomography [1-5], magnetic reso-
nance imaging (MRI) [6-9], ultrasound (US) [11-13] 
and near-infrared fluorescence imaging (NIR) [14-17].  
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Both targeted therapeutics and molecular imag-
ing agents have already been shown to be highly 
suitable materials for facilitating disease diagnosis 
and therapy. Therefore cell-  and tissue-specific tar-
geting with so-called theranostic agents, which com-
bine diagnostic and therapeutic properties within a 
single formulation, are more and more considered to 
be one of the next major leaps forward for enabling 
personalized medicine [17-19]  
With regard to this expanding field of 
theranostics, our considerations focused on receptor 
expression by tumor cells and tumor blood vessels. 
The expression of the αvβ3 integrin receptor, for in-
stance, is hardly detectable in normal (endothelial) 
cells, but on tumor blood vessels and (certain) tumor 
cells, it is highly overexpressed. This fact has already 
been shown to enable effective discrimination be-
tween the tumor and surrounding healthy tissue, as 
exemplified e.g. by studies in which cyclic RGD 
(cRGD) was coupled to PET, MRI, US and NIR imag-
ing agents, such as 18F,  68Ga,  64Cu, gadolinium, iron 
oxides, microbubbles, quantum dots and Cy5.5 [2, 3, 
5, 6-8, 11, 13-16, 20]. 
The use of RGD peptides for cell-  and tis-
sue-targeting permits to achieve much higher local 
concentrations of active and imaging molecules at the 
pathological site compared to non-specific agents. 
Therefore, we here expand our modular peptide nu-
cleic acid (PNA)-based BioShuttle delivery platform 
[5, 21-24] with a cyclic(RGDfK) molecule, targeted to 
the αvβ3 integrin receptor overexpressed by endothe-
lial and (certain) cancer cells. We describe its func-
tionalization with a tetramer containing the chemo-
therapeutic agent temozolomide (TMZ) and/or an 
NIR imaging agent based on Cy7. An advanced click 
chemistry-based approach, based on the 
Diels-Alder-Reaction with inverse electron demand 
(DARinv) [24-28] enabled the simple and straightfor-
ward functionalization of the cRGDfK-containing 
PNA-based carrier construct. Several different con-
structs were prepared (cRGD-TMZ4, 
cRGD-TMZ3-Cy71, cRGD-TMZ2-Cy72  and 
cRGD-Cy74) and they were evaluated in vitro with 
regard to cellular uptake and induction of cell death. 
In addition, the suitability of cRGD-Cy74 for NIR flu-
orescence imaging was evaluated in an appropriate 
animal phantom. The results show that cRGD-based 
carriers containing TMZ and/or Cy7 were effectively 
taken up by αvβ3  integrin expressing MCF7 breast 
cancer cells, that they were more effective in inducing 
cell death than free TMZ, and that they could be 
quantitatively visualized in a XFM-2 mouse phantom.  
Material & Methods 
Cell culture 
Estrogen-sensitive MCF7 human adenocarcino-
ma breast cancer cells (DKFZ, Dept. B040) were used. 
They were cultured and maintained at 37°C in a 5% 
CO2  atmosphere in DMEM (Gibco, Germany), sup-
plemented with 10% fetal calf serum (Biochrome, 
Germany).  
Synthesis of TMZ-tetrazine diene (1) as reaction 
partner for DARinv  
Compound 1 (Figure 1) was synthesized by the 
reaction of 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo 
[4.3.0]nona-2,7,9-triene-9-carboxamide {te-
mozolomide – TMZ (Sigma-Aldrich, Germany)} with 
N-(2-aminopropyl)-4-(6-(pyrimidine-2-yl)-1,2,4,5-tetra
zine-3-yl)benzamide [28]. This compound acts as the 
dienophile component in DARinv. 
 
 
 
Figure 1.  Chemical structure of 4-methyl-5-oxo- 
2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide 
covalently attached to the ε-amino group of lysine which in turn is 
bound to the carboxamide group of 
N-(2-aminopropyl)-4-(6-(pyrimidine-2-yl)-1,2,4,5-tetrazine-3-yl)b
enzamide (1) [28]. 
 
 
Synthesis of Reppe anhydride derivative (2) – 
corresponding DARinv reaction partner 
The synthesis of tetracyclo-[5.4.21,7.02,6.08,11]3,5- 
dioxo-4-aza-9,12-tridecadiene  2  was documented by 
Reppe  [29]. The detailed chemical reaction steps to 
obtain the corresponding acetic acid chloride deriva-
tive 2 (Figure 2) are described in [30]. 
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Figure 2.  Chemical structure of the Reppe Anhydride 2-amino 
acetic acid (glycine) chloride derivative (2). 
 
Synthesis of the functionalized amide-monomer 
Reppe anhydride (3) for the backbone 
The synthesis of Fmoc-protected 
(2-aminoethyl)glycine  (PNA backbone without nu-
cleobase) was documented by Atherton and Sheppard 
[31]. The reaction product 3 is shown in Figure 3 and 
was prepared as described in [30].  
 
 
 
Figure 3.  Chemical structure of Fmoc protect-
ed-[(2-aminoethyl)glycine]  monomer N-functionalized with the 
glycine derivative of Reppe Anhydride (3). 
 
Synthesis of the cRGD-amide tetramer func-
tionalized with the Reppe anhydride (4) 
The synthesis of c(RGDfK)-tetra-(2- 
aminoethyl)glycine  peptide functionalized with the 
Reppe anhydride 3 was carried out by Fmoc-based 
solid phase synthesis. In a similar approach as pub-
lished by Kubas et al. [32], all reaction steps were 
conducted on solid phase. The reaction scheme for the 
whole peptide synthesis is shown in Figure 4. All 
amino acid derivatives as well as the resin were ob-
tained from Merck (Germany). The protected peptidyl 
resin was manually built on 2-chlorotrityl resin (1.5 
mmol/g, 0.1 mmol scale). As the first amino acid, 
Fmoc-Asp-OAll was coupled to the resin in di-
chloromethane in the presence of 
N,N-diisopropylethylamine (DIPEA). After 16 h reac-
tion time, free reaction sites on the resin were blocked 
(dichloromethane: methanol: DIPEA; 17:2:1, v/v/v, 3 
 30 min). The other four Fmoc-protected amino acid 
derivatives [Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, 
Fmoc-Lys(Dde)-OH and Fmoc-D-Phe-OH] were suc-
cessively condensed using 2-(1H-benzotriazole- 
1-yl)-1,1,3,3-tetramethyluronium hexafluorophos-
phate (HBTU) for activation in the presence of DIPEA 
in DMF, allowing a reaction time of 45 to 60 min for 
each amino acid. Fmoc-deprotection was performed 
by treatment of the resin with 50 % (v/v) piperi-
dine-DMF for 2 and 5 min. For the ring formation, the 
allyl protection group was cleaved using 
tetrakis(triphenylphosphine)-palladium (0.3 eq.) as a 
catalyst in dichloromethane containing morpholine 
(25 eq.). After 3 h reaction time, the resin was washed 
first with 5% DIPEA in DMF (5  5 min) and then 
with 0.1 % sodium diethyldithiocarbamate in DMF (5 
 5 min). After Fmoc deprotection of the N-terminal 
amino acid, ring closure was conducted using 
6-chlorohydroxybenzotriazole (PyCLOCK) (5 eq.) and 
DIPEA (5 eq.) in DMF for 17 h. For the conjugation of 
the Reppe Anhydride containing amino acids, the 
ε-amino function of Lys was selectively deprotected 
by treatment of the resin with 2 % hydrazine mono-
hydrate in DMF for 3 h. To the Lys residue the Fmoc 
protected diene derivatives were successively  con-
densed four times as described above and the N ter-
minal acid was acetylated. Cleavage from the resin as 
well as side-chain deprotection of the amino acid de-
rivatives was achieved by treatment with 95 % TFA, 
2.5 % TIS and 2.5 % water for 4 h. Purification of 4 was 
performed by semi-preparative reversed-phase HPLC 
(Dionex (Idstein, Germany): Ultimate 3000 
LPG-3400A pump and variable four wavelength Ul-
timate 3000 VWD-3400RS UV/VIS detector (222 nm, 
254 nm, 280 nm); column: Chromolith Performance 
RP-18e column (100   10 mm; Merck, Darmstadt, 
Germany). The solvent gradient was raised from 5 % 
to 100 % acetonitrile in 5 min at a flow rate of 6 
mL/min. The aqueous phase consisted of water con-
taining 0.1 % TFA. tR = 3.58 min). The identity of the 
reaction  product 4 (Figure 5A) was confirmed by 
MALDI-TOF-MS (m/z calculated for C101H119N21O24 
([M+H]+):  2012.15 found 2012.1) (Figure 5C). 
MALDI-TOF-MS was performed on a Microflex LT 
(Bruker Daltonics, Bremen, Germany). 
 Theranostics 2011, 1 
 
http://www.thno.org 
384 
 
Figure 4. A) Shows the chemical structure of 4, the cRGD-peptide derivatized with tetra-[(2-aminoethyl)glycine] N-functionalized 
Reppe Anhydride. B) Synthetic route for the preparation of 4. The solid phase support is depicted by the grey circle. (a) condensation of 
the first amino acid; (b) stepwise elongation on 2-chlorotrityl resin; (c) cyclization steps: 1. Pd(PPh3)4, morpholine; 2. PyCLOCK, DIPEA; 
(d) conjugation to Reppe Anhydride derivative: 1. Hydrazine monohydrate; 2. Stepwise elongation, 3. Acetylation; (e) cleavage from resin 
and deprotection: TFA, TIS, water. C) The upper panel shows the HPLC chromatogram of the purified peptide 4. The solvent gradient 
was raised from 5 % to 100 % acetonitrile in 5 min (starting immediately) at a flow rate of 6 ml/min. The aqueous phase consisted of water 
containing 0.1 % TFA. The lower panel shows the MALDI-TOF spectrum of the purified peptide 4. Theranostics 2011, 1 
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Figure 5. A) Chemical structure of the reaction product 5 (described as variant I, Table 1) after ligation of 4 and 1 by use of the DARinv. 
B) HPLC chromatogram of purified 5. For HPLC conditions see Figure 4C. Theranostics 2011, 1 
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Synthesis of cRGD-TMZ
4 (5) 
In order to realize sufficiently high local concen-
trations to kill target cells, such as αvβ3 integrin ex-
pressing MCF7 cells, a targeted TMZ-conjugate with 
similarities to the previously documented 
cRGD-BioShuttle-TMZ was designed and synthesized 
[27]. Here, with the aim of enhancing the toxic effects 
against target cells, we connected the cRGD targeting 
peptide to a tetramer of PNA amide backbone-based 
building blocks functionalized with TMZ. The chem-
ical synthesis of the cRGD-TMZ4 (5) was carried out 
by the reaction of peptide 4 with 1 in the DARinv ac-
cording to the protocol described in [27, 30]. The 
compound was purified by semi-preparative HPLC 
(system and conditions see above, tR = 3.13 min). Its 
structure as well as the HPLC chromatogram are 
shown in Figure 5. 
Synthesis of Cy7 functionalized with a diaryl 
diene component (6) 
The ligation of Cy7 with N-(2-aminopropyl)-4-(6- 
(pyrimidine-2-yl)-1,2,4,5-tetrazine-3-yl)benzamide 
was performed as described in [28]. 
 
Figure 6.  Chemical structure of the indotricarbocyanine dye 
Cy7-tetrazine diene component 6 suitable for ligation by DARinv 
with 4. 
Synthesis of cRGD-TMZ
3-Cy7
1, 
cRGD-TMZ
2-Cy7
2, and cRGD-Cy7
4 
In order to evaluate the dose-dependent sensi-
tivity of Cy7 in NIR imaging as well as the TMZ me-
diated treatment response, we designed the following 
variants based on the cRGD-Lys-PNA-like am-
ide-tetramer 4 by use of the DARinv with Cy7-tetrazine 
diene 6 and TMZ-tetrazine diene 1, respectively (Ta-
ble 1). 1 and 6 each react as the diene components 
whereas the Reppe anhydride in 4 functions as the 
dienophile reaction partner. Variant II possesses one 
Cy7 and three TMZ, variant III  two Cy7 and two 
TMZ, and variant IV four Cy7. By reaction of 4 with 
equimolar amounts of 1 and 6, respectively, a mixture 
of II and III was obtained which could be separated 
by semi-preparative HPLC (system and conditions 
see above; tR(II) = 3.63 min, tR(III) = 3.95 min). The 
HPLC chromatograms of II, III, and IV are shown in 
Figure 7. The identity of the compounds was con-
firmed by ESI-MS. 
 
 
 
 
Table 1. Overview of the cRGD-TMZ-Cy7 conjugates 
(I-IV) used in this study: 
    cRGD variants  TMZ  CY7 
I    cRGD-TMZ4  4  - 
II    cRGD-TMZ3-Cy71  3  1 
III    cRGD-TMZ2-Cy72  2  2 
IV    cRGD-Cy74  -  4 
 
 
 
 
Figure 7.  HPLC chromatograms of II (A), III (B) and IV (C). See Figure 4C for HPLC conditions. 
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NIR Fluorescence measurements of the Cy7 de-
rivatives 
In order to characterize the fluorescence proper-
ties of the Cy7 containing constructs, excitation and 
emission measurements were performed. On the basis 
of the stock solution (1g substance / L), the following 
dilution series was prepared: 1:10, 1:50, and 1:500. The 
corresponding emission intensities of the Cy7 deriva-
tives were measured in the spectral range between 
400 and 800 nm. The following Cy7 derivatives were 
measured:  
•  cRGD-Cy74 (IV, Table 1) 
•  cRGD-TMZ3-Cy71 (II, Table 1) 
•  the Cy7-tetrazine diene component 6 alone was 
investigated under identical conditions 
Confocal Laser scanning microscopy (CLSM) 
In order to reconfirm our data documenting the 
internalization  of the cRGD into the cytoplasm of 
MCF-7 breast cancer cells we used the confocal laser 
scanning microscope (CLSM) of the Microscopy Core 
Facility of the German Cancer Research Center for 
qualified verification of the data. The pictures were 
taken with a Leica confocal microscope TCS SP5 II 
(excitation at 740 nm, emission at 780 nm) and exam-
ined with the Leica LAS-Software. 24 hours before 
CLSM measurements the MCF-7 cells (5×105), were 
cultivated in 8-well cell culture plates (Lab-Tek
) and 
treated with cRGD-TMZ2-Cy72 (III, Table 1) (3.7, 11, 
33, and 100 µM) (Figure 11).  
Mouse phantom study 
A phantom study [XFM-2 Fluorescent Mouse 
phantom (Xenogen Corp)] was performed to assess 
the optical properties of cRGD-CY74  (IV) and 
cRGD-TMZ3-Cy1  (II) for its potential use in small 
animal imaging. As the probe had an absorption 
maximum at 745 nm (Figure 8), it was excited with a 
733 nm diode laser (20 mW) equipped with an addi-
tional 740 nm-13 band-pass filter, to limit the band-
width of excitation light. Emitted light was detected 
with a Hamamatsu ORCA ER camera (-45 °C, high 
gain, no binning, lens F-number 2.8), equipped with a 
786 nm-22 band-pass filter to filter out the excitation 
light. The concentration of the probes was 1, 10 and 
100 nM, respectively, and the measurements were 
performed in capillaries either in the mouse phantom 
or without the mouse phantom. 
Treatment of MCF7 breast cancer cells 
TMZ, cRGD-TMZ4  (I), and cRGD-TMZ2-Cy72 
(III) were dissolved in 10 % aqueous solution. MCF7 
cells were grown as subconfluent monolayers in 
DMEM (control) and in DMEM containing appropri-
ate amounts of TMZ, cRGD-TMZ4  and 
cRGD-TMZ2-Cy72, respectively, (100, 33, 11, and 3.7 
µM), and their effects were analyzed 48 h after treat-
ment.  
Multiparametric flow cytometry analysis 
Experiments were performed using a Galaxy Pro 
flow cytometer (PARTEC, Germany), equipped with a 
488 nm laser and 635 nm laser diode, with filter com-
bination for Cy7. The use of the flow cytometry pa-
rameters forward (FSC) and sideward (SSC) scatter of 
the cells give an indication on drug effects through the 
relative cell size and structural effects such as granu-
larity.  
 
 
Figure 8. The diagram shows the absorption spectra of the Cy7 
tetrazine diene component 6 (A, B, C) and cRGD-TMZ3-Cy71 II 
(D, E, F). A) Dark blue:  6: dilution: 1:10; B) Magenta: 6: dilution 
1:50;  C) Blue: 6: dilution 1:500; D) Green: II: dilution 1:10; E) Dark 
brown: II: dilution 1:50; F) Dark gray: II: dilution 1:500; The red 
arrows point to the shoulders (710 – 740 nm). The dashed blue 
arrows point to the maxima of D and E shifted on the wavelength 
axis towards 800 nm.  
 
Results 
Absorption spectra 
First, we characterized the absorption spectra of 
the synthesized Cy7 fluorescent diene component 6, 
which is ready for DARinv. As depicted in Figure 8 
A-C, the measurements showed a maximum at 745 
nm and a shoulder at 710 and 740 nm, dependent on 
the concentration of the measured solutions. We ob-
served decreasing absorption magnitudes (0.6, 0.3, 
0.05) in relation to the dilution from 1:10, 1:50, to 1:500 Theranostics 2011, 1 
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of the Cy7-tetrazine diene component 6. As exempli-
fied by the curves in Figure  8  D-E, the absorption 
measurements of the reaction product 
cRGD-TMZ3-CY71  (after DARinv  ligation) showed a 
shift of the maximum to ∼800 nm and a similar dilu-
tion-dependent decrease in absorption height (0.325 
and 0.125; for 1:10 and 1:50 dilutions, respectively). At 
a dilution of 1:500 no maximum absorption peak was 
observed for cRGD-TMZ3-Cy71. 
Phantom study 
The cRGD-Cy74 conjugate (IV, Table 1) was de-
signed as a prototype to investigate NIR efficiency 
parameters, like refinement of spatial resolution and 
sensitivity of the NIR methodology. In order to assess 
the optical properties of cRGD-TMZ3-Cy71  (II) and 
cRGD-Cy74 (IV) for its potential use in preclinical in 
vivo imaging, two experimental phantom studies were 
performed. The first set of experiments focused on 
capillaries [cRGD-TMZ3-Cy71  (II,  Table 1) and 
cRGD-Cy74 (IV, Table 1)] placed in direct view of the 
camera. This setup was chosen to suppress photon 
scattering and absorption, and served to quantita-
tively detect the yield of emitted light related to probe 
concentration. Data were obtained for three different 
probe concentrations, and integrated intensity values 
were calculated in the indicated ROIs of the projection 
images. As shown in Figure 9, the observed values 
correlated linearly to the probe concentrations. The 
fluorescence intensities of  IV  (cRGD-Cy74)  are ten 
times higher as measured in II (cRGD-TMZ3-Cy71).  
 
 
 
Figure 9.  NIR intensity data acquisition in 0.9 mm capillary sources filled with three different concentrations of the cRGD-TMZ3-Cy71 
(II) and the cRGD-Cy74 (IV). Counts are normalized for exposure time. Theranostics 2011, 1 
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Figure 10.  NIR intensity data acquisition of three different quantities of cRGD-Cy74 (IV) placed inside rod opening A of the XFM-2 
Fluorescent Mouse phantom (Xenogen Corp.). Counts are normalized for exposure time. Integrated intensity values are taken from the 
ROIs as indicated.  
 
In a second set of imaging experiments we in-
vestigated the XFM-2 Fluorescent Mouse phantom 
(Xenogen Corp.). This phantom approximates the 
optical properties of tissues, such as scattering and 
light attenuation with respect to the corresponding 
wavelength range. As shown in Figure 10, the Cy7 
signal was detected at concentration levels that are 
commonly used in animal studies. It is evident that 
the fluorescence intensities of II (cRGD-TMZ3-Cy71) in 
the mouse phantom differ only slightly from IV 
(cRGD-Cy74) with four Cy7 fluorophores per mole-
cule. Importantly, in line with the results obtained in 
the capillary experiment (Figure 9) the signal intensi-
ties correlated linearly with the concentration of the 
probe. 
Cellular localization of Cy7 using Confocal Laser 
Scanning Microscopy (CLSM) 
In order to investigate the cellular localization of 
cRGD-TMZ4 (I, Table 1), we designed a variant car-
rying two Cy7 moieties and two TMZ moieties 
(cRGD-TMZ2-Cy72, III, Table 1). This probe was ap-
plied to the culture media of avβ3 integrin-expressing Theranostics 2011, 1 
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MCF7 cells. As shown in Figure 11 after 48 h of incu-
bation with III, a clear perinuclear Cy7 fluorescence 
signal was observed. Line α of Figure 11 represents 
the merged pictures of β (DIC) and γ (fluorescence). 
At a concentration of 33 µM, damage of cellular 
structures was evident. This observation was con-
firmed at concentrations of 100 µM, where no mor-
phologically intact cells were visible. This can be 
clearly seen in the DIC pictures in Line β: at a con-
centration of 3.7 µM of cRGD-TMZ2-Cy72, physiolog-
ically intact structures could still be observed. At 11 
µM, cellular structures were adelomorphic, and at a 
concentration of 33 µM, solely disintegrated cell mass 
was observed. It is interesting to note that at this 
concentration the cellular structures were still visible 
in the fluorescence images (Line γ), but absent in DIC. 
The cRGD-TMZ2-Cy72  appears to shrink the MCF7 
cells. Upon treatment with a concentration of 100 µM, 
no morphologically intact cell structures could be 
observed any more. 
 
 
Figure 11.  The figure shows CLSM pictures of MCF7 breast cancer cells after application of cRGD-TMZ2-Cy72 (III, Table 1). The 
columns of the figure illustrate the increasing concentrations of cRGD-TMZ2-Cy72 from left to right: 3.7, 11, 33, and 100 µM.  Theranostics 2011, 1 
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Multiparametric FACS analysis 
To further investigate the effects of free and 
cRGD-targeted TMZ on the structures of MCF7 cells, 
multiparametric flow cytometry was performed 
(Figure 12). We tested two major parameters: R1 rep-
resents the relative amount of cells (counts), and R2 
represents the granularity, which is influenced by the 
morphology of the cell, the structure of the nuclei and 
the quantity of cytoplasmic compartments (such as 
mitochondria, Golgi, etc). The morphological param-
eters of the FACS analysis revealed an almost unal-
tered cell size in untreated cells (line 1), as well as in 
cells which were treated with free TMZ at a concen-
tration of 33 µM (line 2). In contrast to this, the gran-
ularity changed and showed an increased fraction of 
more granulized cells upon treatment with 
cRGD-TMZ2-Cy72 (III, Table 1). The MCF7 cell frac-
tion with the highest amount of granularity (29.4 %) 
appeared after treatment at a concentration of 33 µM. 
At a concentration of 100 µM, no morphologically 
intact cells could be detected, which is in line with the 
results presented in Figure 11. Also in line with the 
results in Figure 11, when using FACS to analyze Cy7 
uptake, it was found that cRGD-TMZ2-Cy72 was ef-
fectively taken up by MCF7 cells (Figure 12, line 3-5). 
Increased relative fluorescence intensity for 
cRGD-TMZ2-Cy72  could be detected, too. Both pa-
rameters suffice for a rough cell characterization.  
 
 
 
 
Figure 12.  FACS analysis demonstrating the effects of free TMZ and different concentrations of cRGD-TMZ2-Cy72 (III, Table 1) on cell 
granularity and on cell size. It can be seen that cell size (R1) and granularity (R2) barely differed between untreated control cells and cells 
treated with free TMZ. For cRGD-TMZ2-Cy72, cell granularity increased with increasing dose. Upon incubation with 100 µM of 
cRGD-TMZ2-Cy72, no cells survived, and the detection of morphological changes was not possible. 
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Discussion 
Significant advances in genetics and proteomics 
in the past two decades resulted in a paradigm shift in 
(anticancer) drug therapy, from standard (mostly 
low-molecular-weight) chemotherapeutic drugs, to 
molecularly targeted therapeutic interventions. In 
parallel, molecular information and targeting strate-
gies also started to influence the diagnostic field, giv-
ing rise to more disease-specific diagnostic agents and 
to molecular imaging techniques. The term molecular 
imaging was introduced approximately ten years ago, 
and is used to describe the diagnostic field which fo-
cuses on the analysis of biological processes at the 
molecular level, including e.g. receptor expression 
and enzyme activity [33]. Molecular imaging is con-
sidered as a pivotal technology for facilitating tar-
geted (and personalized) therapy, enabling e.g. the 
distinction of malignant tissue from surrounding 
healthy tissue, the staging of tumors as well as the 
selection of therapeutics on the basis of receptor ex-
pression, and the visualization and staging of (mi-
cro)metastases.  
In recent years, more and more attempts were 
made to combine (molecular) imaging and (targeted) 
therapy, giving rise to the highly innovative and 
highly interdisciplinary field of theranostics [17-20, 
34]. Having these efforts in mind, we prepared an αvβ3 
integrin targeted BioShuttle-based carrier material [5, 
21-24, 35], consisting of amide-based building blocks 
whose backbone originates from peptide nucleic acids 
(PNA) [36-40]. We functionalized this BioShuttle with 
the alkylating chemotherapeutic agent temozolomide 
(TMZ) and the NIR dye indotricarbocyanine  (Cy7). 
We previously showed that the cytotoxic effects of 
TMZ connected to a BioShuttle-based carrier material 
were increased through elevation of the local TMZ 
concentration at the surface of and inside αvβ3 integrin 
expressing cancer cells as compared to free TMZ [27]. 
Encouraged by these initial results, we here extended 
our efforts by synthesizing variants of this construct, 
in which the PNA-based and cRGD-targeted carrier 
moiety was functionalized with different amounts of 
TMZ and Cy7. Cellular granularity, which is known 
to be an adequate FACS parameter for assessing the 
morphological changes of cells upon exposure to cy-
totoxic agents [41], was used to evaluate the effect of 
(targeted) TMZ treatment on the induction of cell 
death. As expected, an increase in the granularity of 
MCF7 cells was observed upon exposing them to in-
creasing concentrations of cRGD-targeted TMZ. This 
finding was corroborated by the fact that no mor-
phologically intact MCF7 cells could be observed us-
ing CLSM after exposing them to high concentrations 
of this agent. These results show that 
cRGD-TMZ2-Cy72  is (much) more potent as a cyto-
toxic agent compared to TMZ alone, which may be 
due on the one hand to the αvβ3 targeting cRGD moi-
ety and on the other hand to the incorporation of two 
TMZ moieties. 
To visualize the cRGD-targeted TMZ-containing 
constructs, the NIR dye Cy7 was incorporated. It is 
interesting to note that the absorption measurements 
of the Cy7-tetrazine precursor 6, the reaction partner 
for inverse Diels-Alder (DARinv)-based click chemis-
try, revealed an absorption maximum of 745 nm and 
that this maximum shifted to approximately 800 nm 
after ligation to the carrier material. To what extent 
fluorescence resonance energy transfer effects are 
involved in the shift of the absorption maximum to-
ward 800 nm remains to be clarified. Analogous NIR 
imaging studies with Cy7-labeled neutrophil-specific 
agents showed no differences in spectra between 
non-conjugated and peptide-conjugated Cy7 dyes 
[42]. The fact that the Cy7 precursor used here is li-
gated to a diaryl-tetrazine, acting as a diene reaction 
partner for the DARinv, might explain this shift, but 
further experiments are required to confirm this as-
sumption. Using capillaries and the XFM-2 phantom, 
which simulates the scattering and light attenuation 
of tissues in mice, we finally confirmed that the pre-
pared Cy7-containing constructs are highly suited for 
NIR fluorescence imaging. Strong signals were ob-
served even at a dose of 1 nM, and signal intensities 
linearly correlated with the concentrations of the 
probes. Remarkable is the fact that the use of probe II 
with one Cy7 as an imaging molecule 
(cRGD-TMZ3-Cy71)  is sufficient for imaging as ob-
served in the mouse phantom studies. The measure-
ments of construct IV containing four Cy7 molecules 
(cRGD-Cy74) did not show much higher fluorescence 
intensities. This offers the possibility of conjugating 
other imaging or therapeutic probes to the versatile 
BioShuttle backbone, e.g. a chelator for radiometal 
complexation and/or an additional drug, in order to 
obtain multimodal theranostic formulations for sim-
ultaneously delivering multiple chemotherapeutic 
drugs to cancer cells. The results obtained here pro-
vide some initial experimental evidence in this direc-
tion, showing that cRGD-TMZ2-Cy72  might be a 
promising agent for targeted therapy combined with 
optical imaging of tumors. Experiments to validate 
these findings in living mice, as well as studies to 
evaluate the in vivo antitumor efficacy of these integ-
rin-targeted theranostic agents, are planned for the 
near future.  Theranostics 2011, 1 
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Conclusion  
Using the inverse Diels-Alder reaction, several 
different BioShuttle-PNA constructs targeted to αvβ3 
integrins and functionalised with TMZ as a therapeu-
tic agents and with Cy7 as an imaging agent were 
prepared. One of these compounds, i.e 
cRGD-TMZ2-Cy72, showed enhanced cytotoxicity as 
compared to free TMZ, as well as very  favourable 
imaging properties in NIR measurements. These re-
sults provide initial proof-of-principle for the poten-
tial of this formulation to be used as a theranostic 
agent. Follow-up experiments are currently underway 
to validate the usefulness of cRGD-TMZ2-Cy72 in tu-
mor-bearing animals. 
Acknowledgment 
This work was supported by the Deutsche 
Krebshilfe, D-53004 Bonn; Grant Number: 106335. The 
authors are thankful to Gabriele Müller, Biophysics of 
Macromolecules Department, DKFZ and Melanie 
Grundl, University of Applied Sciences, Mannheim 
for their encouragement. 
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
1.  Pan D, Gambhir SS, Toyokuni T, et al. Rapid synthesis of a 
5'-fluorinated oligodeoxy-nucleotide: a model antisense probe 
for use in imaging with positron emission tomography (PET). 
Bioorg Med Chem Lett. 1998; 8: 1317-20. 
2.  Chen X, Hou Y, Tohme M, et al. Pegylated Arg-Gly-Asp 
peptide:  64Cu labeling and PET imaging of brain tumor 
αvβ3-integrin expression. J Nucl Med. 2004; 45: 1776-83. 
3.  Beer AJ, Kessler H, Wester HJ, et al. PET Imaging of Integrin 
αvβ3 Expression. Theranostics. 2011; 1: 48-57. 
4.  Mühlhausen U, Komljenovic D, Bretschi M, et al. A novel PET 
tracer for the imaging of αvβ3 and αvβ5 integrins in experimental 
breast cancer bone metastases. Contrast Media Mol. Imag. 2011; 
in press. 
5.  Heckl S, Pipkorn R, Waldeck W, et al. Intracellular 
Visualization of Prostate Cancer Using Magnetic Resonance 
Imaging. Cancer Res. 2003; 63: 4766-72. 
6.  Mulder WJ, Strijkers GJ, van Tilborg GA, et al. Lipid-based 
nanoparticles for contrast-enhanced MRI and molecular 
imaging. NMR Biomed. 2006; 19: 142-64. 
7.  Zhang C, Jugold M, Woenne EC, et al. Specific targeting of 
tumor angiogenesis by RGD-conjugated ultrasmall 
superparamagnetic iron oxide particles using a clinical 1.5-T 
magnetic resonance scanner. Cancer Res. 2007; 67: 1555-62. 
8.  Tan M, Lu Z-R. Integrin targeted MR imaging. Theranostics. 
2011; 1: 83-101. 
9.  Kaufmann BA, Lindner JR. Molecular imaging with targeted 
contrast ultrasound. Curr Opin Biotechnol. 2007; 18: 11-6. 
10.  Klibanov AL. Ultrasound molecular imaging with targeted 
microbubble contrast agents. J Nucl Cardiol. 2007; 14: 876-84. 
11.  Palmowski M, Huppert J, Ladewig G, et al. Molecular profiling 
of angiogenesis with targeted ultrasound imaging: early 
assessment of antiangiogenic therapy effects. Mol Cancer Ther. 
2008; 7: 101-9. 
12.  Kiessling F, Gaetjens J, Palmowski M. Application of molecular 
ultrasound for imaging integrin expression. Theranostics. 2011; 
1: 127-34. 
13.  Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence 
imaging of integrin αvβ3 in brain tumor xenografts. Cancer Res. 
2004; 64: 8009-14. 
14.  Cheng Z, Wu Y, Xiong Z, et al. Near-infrared fluorescent RGD 
peptides for optical imaging of integrin αvβ3  expression in 
living mice. Bioconjug Chem. 2005; 16: 1433-41. 
15.  Cai W, Shin DW, Chen K, et al. Peptide-labeled near-infrared 
quantum dots for imaging tumor vasculature in living subjects. 
Nano Lett. 2006; 6: 669-76. 
16.  Ye Y, Chen X. Integrin targeting for tumor optical imaging. 
Theranostics. 2011; 1: 102-26. 
17.  Warner S. Diagnostics + Therapy = Theranostics. The Scientist. 
2004; 18: 38. 
18.  Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. 
Adv Drug Deliv Rev. 2010; 62: 1064-79. 
19.  Lammers T, Kiessling F, Hennink WE, et al. Nanotheranostics 
and image-guided drug delivery: current concepts and future 
directions. Mol Pharm. 2010; 7: 1899-912. 
20.  Chen X. Integrin Targeted Imaging and Therapy. Theranostics. 
2011; 1: 28-9. 
21.  Braun K, Peschke P, Pipkorn R, et al. A biological transporter 
for the delivery of peptide nucleic acids (PNAs) to the nuclear 
compartment of living cells. J Mol Biol. 2002; 318: 237-43. 
22.  Pipkorn R, Debus J, Waldeck W, et al. Synthesis of functional 
peptides for therapy of HPV 18 positive hela cervix cancer cells. 
Biopolymers. 2003; 71: 409. 
23.  Braun K, von Brasch L, Pipkorn R, et al. BioShuttle-mediated 
plasmid transfer. Int J Med Sci. 2007; 4: 267-77. 
24.  Pipkorn R, Waldeck W, Didinger B, et al. 
Inverse-electron-demand Diels-Alder reaction as a highly 
efficient chemoselective ligation procedure: Synthesis and 
function of a BioShuttle for temozolomide transport into 
prostate cancer cells. J Pept Sci. 2009; 15: 235-41. 
25.  Wiessler M, Waldeck W, Kliem C, et al. The 
Diels-Alder-reaction with inverse-electron-demand, a very 
efficient versatile click-reaction concept for proper ligation of 
variable molecular partners. Int J Med Sci. 2009; 7: 19-28. 
26.  Pipkorn R, Wiessler M, Waldeck W, et al. TMZ-Bioshuttle, An 
Exemplary Drug Reformulation by Inverse Diels Alder Click 
Chemistry. Biopolymers. 2009; 92: 350-1. 
27.  Braun K, Wiessler M, Pipkorn R, et al. A cyclic-RGD-BioShuttle 
functionalized with TMZ by DARinv "Click Chemistry" 
targeted to αvβ3 integrin for therapy. Int J Med Sci. 2010; 7: 
326-39. 
28.  Wiessler, M, Kliem, C, Lorenz, P, Mueller, E, and Fleischhacker, 
H. EU Patent: Ligation reaction based on the Diels Alder 
Reaction with invers electron demand. 2006; [EP 06 012 414.6].  
29.  Reppe W, Schlichting O, Klager K, et al. Cyclisierende 
Polymerisation von Acetylen I. Justus Liebigs Ann Chem. 1948; 
560: 1-92. 
30.  Wiessler M, Waldeck W, Pipkorn R, et al. Extension of the PNA 
world by functionalized PNA monomers eligible candidates for 
inverse Diels Alder Click Chemistry. Int J Med Sci. 2010; 7: 
213-23. 
31.  Atherton E, Sheppard RC. In: Undenfriend S, Meienhofer J, 
editors. The Peptides. Orlando: Academic Press. 1987:1-38. 
32.  Kubas H, Schäfer M, Bauder-Wüst U, et al. Multivalent cyclic 
RGD ligands: influence of linker lengths on receptor binding. 
Nucl Med Biol. 2010; 37: 885-91. 
33.  Weissleder R, Mahmood U. Molecular imaging. Radiology. 
2001; 219: 316-33. Theranostics 2011, 1 
 
http://www.thno.org 
394 
34.  Lammers T, Aime S, Hennink WE, et al. Theranostic 
Nanomedicines. Acc Chem Res. 2011; 44: 1029-38. 
35.  Heckl S, Debus J, Jenne J, et al. CNN-Gd(3+) Enables Cell 
Nucleus Molecular Imaging of Prostate Cancer Cells: The Last 
600 nm. Cancer Res. 2002; 62: 7018-24. 
36.  Nielsen PE,  Egholm M, Berg RH, et al. Sequence-selective 
recognition of DNA by strand displacement with a 
thymine-substituted polyamide. Science. 1991; 254: 1497-500. 
37.  Egholm M, Buchardt O, Christensen L, et al. PNA hybridizes to 
complementary oligonucleotides obeying the Watson-Crick 
hydrogen-bonding rules [see comments]. Nature. 1993; 365: 
566-8. 
38.  Demidov VV, Potaman VN, Frank Kamenetskii MD, et al. 
Stability of peptide nucleic acids in human serum and cellular 
extracts. Biochem Pharmacol. 1994; 48: 1310-3. 
39.  Nielsen PE. Applications of peptide nucleic acids. Curr Opin 
Biotechnol. 1999; 10: 71-5. 
40.  Nielsen PE. Peptide nucleic acids and the origin of life. Chem 
Biodivers. 2007; 4: 1996-2002. 
41.  Fletcher MP, Seligmann BE. Monitoring human neutrophil 
granule secretion by flow cytometry: secretion and membrane 
potential changes assessed by light scatter and a fluorescent 
probe of membrane potential. J Leukoc Biol. 1985; 37: 431-47. 
42.  Xiao L, Zhang Y, Liu Z, et al. Synthesis of the Cyanine 7 labeled 
neutrophil-specific agents for noninvasive near infrared 
fluorescence imaging. Bioorg Med Chem Lett. 2010; 20: 3515-7. 